Genesis Biopharma to Hold Business Update Conference Call on June 29

LOS ANGELES, June 22, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that it will hold a conference call with the investment community on Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific).  The Company's Chairman and Chief Executive Officer, Anthony J. Cataldo, will provide an update on the business, and discuss the clinical and commercial development plans for the Company's new autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.  There will also be a question and answer session following the presentation.

Individuals interested in listening to the conference call may do so by dialing 888-634-9408 for domestic callers, or 706-679-0879 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.genesis-biopharma.com.  A slide presentation will accompany the call and webcast, and will be available on the Company website.

A telephone replay will be available through July 1, 2011 by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering the Conference ID #: 78126182.  The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.  Forward-looking statements speak only as of the date they are made.  The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.